After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Three off-the-shelf mRNA therapies join intismeran autogene.
Antibody-drug conjugates hitting this target abound.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
